Alantra advised Pharmamar in the sale of its two non-core business activities: Zelnova & Copyr
SECTORChemicals & Polymers; Industrials
Alantra has advised PharmaMar, a world leader company in the discovery of antitumor drugs of marine origin, on the sale of its 2 non-core business activities: Zelnova Zelita SA & Copyr SpA.
PharmaMar is a company focused on oncology and committed to research and development which takes inspiration from the sea to discover molecules with antitumor properties. The firm seeks innovative products to provide healthcare professionals with new tools to treat cancer. PharmaMar is quoted on the Spanish Stock Market and is looking to be listed on The Nasdaq Stock Market.
The company decided to divest its non-core business activities and engaged Alantra to sell: Zelnova, a non-food consumer goods company that develops and markets (B2B & B2C) cleaning, hygiene and pest control products for the domestic, industrial and hospitality sectors. It is a leader in several segments of the European insecticide market with a strong portfolio of brands for both household and professional use.
Copyr, the pyrethrum company, focuses on pyrethrum and pyrethroids products for professional and amateur use in the agricultural, pest control, industrial and HoReCa (foodservice) segments.
The transaction highlights Alantra’s expertise advising on sell-side processes, managing both strategic and financial interested investors and achieving the best transaction in terms of price and structure for its client.
May 2021Sell-side advisoryValue $60 millionMay 2021SECTOR Chemicals & PolymersService M&AValue $60 million
Mar 2021Sell-side advisoryMar 2021SECTOR Chemicals & PolymersService M&A
Dec 2020Buy-side advisoryDec 2020SECTOR Chemicals & PolymersService M&A
Apr 2020Buy-side advisoryValue RMB 941 millionApr 2020SECTOR Chemicals & PolymersService M&AValue RMB 941 million